BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Operating cash flow minus capital expenditures
Latest
$328.46M
↑ 697% vs avg
Percentile
P100
Near historical high
Streak
3 yr
Consecutive growthExpanding
Average
$-55.05M
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | $328.46M | +718.1% |
| 2024 | $-53.14M | +45.4% |
| 2023 | $-97.31M | +40.4% |
| 2022 | $-163.20M | -12.9% |
| 2021 | $-144.54M | -4.9% |
| 2020 | $-137.73M | -53.2% |
| 2019 | $-89.93M | +3.2% |
| 2018 | $-92.93M | -124.1% |
| 2017 | $-41.47M | +29.4% |
| 2016 | $-58.72M | - |